Global Cancer Immunotherapies Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cancer Immunotherapies Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
Cancer Immunotherapies report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cancer Immunotherapies market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Breast Cancer and Leukemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cancer Immunotherapies industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cancer Immunotherapies key manufacturers include Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc. Amgen, AstraZeneca, Roche are top 3 players and held % sales share in total in 2022.
Cancer Immunotherapies can be divided into Monoclonal Antibodies (MABs), Cancer Vaccines, Immunomodulators and Adoptive Cell transfer, etc. Monoclonal Antibodies (MABs) is the mainstream product in the market, accounting for % sales share globally in 2022.
Cancer Immunotherapies is widely used in various fields, such as Breast Cancer, Leukemia, Lymphoma and Melanoma, etc. Breast Cancer provides greatest supports to the Cancer Immunotherapies industry development. In 2022, global % sales of Cancer Immunotherapies went into Breast Cancer filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Immunotherapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences
Segment by Type
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cancer Immunotherapies market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cancer Immunotherapies, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cancer Immunotherapies industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Cancer Immunotherapies in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cancer Immunotherapies introduction, etc. Cancer Immunotherapies Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cancer Immunotherapies market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Cancer Immunotherapies report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cancer Immunotherapies market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Breast Cancer and Leukemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cancer Immunotherapies industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cancer Immunotherapies key manufacturers include Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc. Amgen, AstraZeneca, Roche are top 3 players and held % sales share in total in 2022.
Cancer Immunotherapies can be divided into Monoclonal Antibodies (MABs), Cancer Vaccines, Immunomodulators and Adoptive Cell transfer, etc. Monoclonal Antibodies (MABs) is the mainstream product in the market, accounting for % sales share globally in 2022.
Cancer Immunotherapies is widely used in various fields, such as Breast Cancer, Leukemia, Lymphoma and Melanoma, etc. Breast Cancer provides greatest supports to the Cancer Immunotherapies industry development. In 2022, global % sales of Cancer Immunotherapies went into Breast Cancer filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Immunotherapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences
Segment by Type
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
Segment by Application
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cancer Immunotherapies market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cancer Immunotherapies, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cancer Immunotherapies industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Cancer Immunotherapies in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cancer Immunotherapies introduction, etc. Cancer Immunotherapies Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cancer Immunotherapies market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices